Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director | February 02, 2022 | February 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Syndax Pharmaceuticals Inc
Report date February 02, 2022 · Filed February 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,000 |
Reported balance
After 2022-02-02 transaction · row 1
1 source rowRow 1 · 2022-02-02 · Grant · Acquired 16,000 · Balance 32,000 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2022 Filed Feb 3, 2022 22:29 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001072 · primarydocument.xml · nonDerivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:06 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 30 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-21-007180 · primarydocument.xml · derivative · entry 6 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2029-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:06 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 14,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001562180-21-007180 · primarydocument.xml · derivative · entry 5 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2028-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:06 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 30 | $18.03 | $540.97 |
DisclosureSEC source: 0001562180-21-007180 · primarydocument.xml · nonDerivative · entry 4 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F2 · price: The sale prices ranged from $18.03 to $19.03. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:06 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 30 | $7.88 | $236.40 |
DisclosureSEC source: 0001562180-21-007180 · primarydocument.xml · nonDerivative · entry 3 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:06 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 14,000 | $18.03 | $252,452.20 |
DisclosureSEC source: 0001562180-21-007180 · primarydocument.xml · nonDerivative · entry 2 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F2 · price: The sale prices ranged from $18.03 to $19.03. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:06 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 14,000 | $8.93 | $125,020.00 |
DisclosureSEC source: 0001562180-21-007180 · primarydocument.xml · nonDerivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 20:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 15,635 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-21-005491 · primarydocument.xml · derivative · entry 3 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2029-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 20:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 15,635 | $15.75 | $246,327.86 |
DisclosureSEC source: 0001562180-21-005491 · primarydocument.xml · nonDerivative · entry 2 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 77,682 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $15.58 to $15.94. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 20:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 15,635 | $7.88 | $123,203.80 |
DisclosureSEC source: 0001562180-21-005491 · primarydocument.xml · nonDerivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:46 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 11,926 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-003670 · primarydocument.xml · derivative · entry 6 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2025-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:46 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 1,683 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-21-003670 · primarydocument.xml · derivative · entry 5 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2029-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:46 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 1,683 | $18.65 | $31,384.92 |
DisclosureSEC source: 0001562180-21-003670 · primarydocument.xml · nonDerivative · entry 4 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 93,317 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:46 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 11,926 | $18.65 | $222,398.43 |
DisclosureSEC source: 0001562180-21-003670 · primarydocument.xml · nonDerivative · entry 3 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,683 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 93,317 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:46 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 1,683 | $7.88 | $13,262.04 |
DisclosureSEC source: 0001562180-21-003670 · primarydocument.xml · nonDerivative · entry 2 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:46 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 11,926 | $7.20 | $85,867.20 |
DisclosureSEC source: 0001562180-21-003670 · primarydocument.xml · nonDerivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,167 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001562180-21-001909 · primarydocument.xml · derivative · entry 6 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 74 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-001909 · primarydocument.xml · derivative · entry 5 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2025-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 74 | $24.31 | $1,799.10 |
DisclosureSEC source: 0001562180-21-001909 · primarydocument.xml · nonDerivative · entry 4 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 106,926 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $23.84 to $25.15. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 10,167 | $24.31 | $247,182.14 |
DisclosureSEC source: 0001562180-21-001909 · primarydocument.xml · nonDerivative · entry 3 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,074 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 106,926 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $23.84 to $25.15. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 74 | $7.20 | $532.80 |
DisclosureSEC source: 0001562180-21-001909 · primarydocument.xml · nonDerivative · entry 2 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 10,167 | $6.35 | $64,560.45 |
DisclosureSEC source: 0001562180-21-001909 · primarydocument.xml · nonDerivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:18 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000925 · primarydocument.xml · nonDerivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:35 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001233 · primarydocument.xml · derivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-12 Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 13:00 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-19-003487 · primarydocument.xml · derivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-06-10 Read SEC document |
| May 23, 2018 Filed May 25, 2018 13:00 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001562180-18-002684 · primarydocument.xml · derivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-05-23 Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 21:00 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001562180-18-000719 · primarydocument.xml · derivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-08 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document |
| May 17, 2017 Filed May 19, 2017 15:26 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001562180-17-002005 · primarydocument.xml · derivative · entry 2 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-05-17 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document |
| May 17, 2017 Filed May 19, 2017 15:26 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001562180-17-002005 · primarydocument.xml · derivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-17 Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 21:25 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $11.81 | $0.00 |
DisclosureSEC source: 0001562180-16-003352 · primarydocument.xml · derivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-10-31 F1 · derivative.exercise_date: One hundred percent (100%) of the total number of shares underlying the option shall vest on October 31, 2017, subject to the reporting person's continuous service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.